The Management Team
We have a world class leadership team guiding us in our quest to develop the best medicines for our best friends.
Be part of the Transformation in veterinary medicine
We love the pets around us – our dogs, cats, and horses we share our lives with. Many of us believe these animals are part of the family, providing us unconditional love and companionship throughout our lives. We have an opportunity for cutting edge treatment when disease and chronic conditions cross our path, but what happens when our animal companions encounter these same issues?
Treatment options for our companion animals shouldn’t be limited
Download the Corporate Presentation to learn more about our strategy, team, and programs.
Read the Recent News from KindredBio.
Looking for More?
See Our Pipeline
KindredBio has an exciting pipeline of high-value products for dogs, cats, and horses in development.
$4.50 
-0.15 (-3.27%)
-0.15 (-3.27%)
|
||||||||||||||||
Kindred Biosciences to Announce First Quarter 2021 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerCompany to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, May 11, 2021. San Francisco, California (May 3, 2021) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2021 financial results on May 11, […]
Kindred Biosciences Announces Acceptance of Parvovirus Antibody Prophylaxis Study Data and Approval of Efficacy Indication
/in Frontpage, Investor, News /by Katja BuhrerUSDA approves the claim that the product is effective for the passive immunization of healthy dogs 13 weeks of age or older against canine parvovirus (CPV) disease Results demonstrated 100% efficacy against the deadly disease, highlighting the potential to address a critical unmet medical need San Francisco, California (April 28, 2021) – Kindred Biosciences, Inc. […]
Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (April 20, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company’s novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that […]